158 related articles for article (PubMed ID: 20864806)
1. Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives.
Ghigna C; De Toledo M; Bonomi S; Valacca C; Gallo S; Apicella M; Eperon I; Tazi J; Biamonti G
RNA Biol; 2010; 7(4):495-503. PubMed ID: 20864806
[TBL] [Abstract][Full Text] [Related]
2. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene.
Ghigna C; Giordano S; Shen H; Benvenuto F; Castiglioni F; Comoglio PM; Green MR; Riva S; Biamonti G
Mol Cell; 2005 Dec; 20(6):881-90. PubMed ID: 16364913
[TBL] [Abstract][Full Text] [Related]
3. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition.
Bonomi S; di Matteo A; Buratti E; Cabianca DS; Baralle FE; Ghigna C; Biamonti G
Nucleic Acids Res; 2013 Oct; 41(18):8665-79. PubMed ID: 23863836
[TBL] [Abstract][Full Text] [Related]
4. SRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene.
Moon H; Cho S; Loh TJ; Oh HK; Jang HN; Zhou J; Kwon YS; Liao DJ; Jun Y; Eom S; Ghigna C; Biamonti G; Green MR; Zheng X; Shen H
Biochim Biophys Acta; 2014 Nov; 1839(11):1132-40. PubMed ID: 25220236
[TBL] [Abstract][Full Text] [Related]
5. RON alternative splicing regulation in primary ovarian cancer.
Mayer S; Hirschfeld M; Jaeger M; Pies S; Iborra S; Erbes T; Stickeler E
Oncol Rep; 2015 Jul; 34(1):423-30. PubMed ID: 25997828
[TBL] [Abstract][Full Text] [Related]
6. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene.
Valacca C; Bonomi S; Buratti E; Pedrotti S; Baralle FE; Sette C; Ghigna C; Biamonti G
J Cell Biol; 2010 Oct; 191(1):87-99. PubMed ID: 20876280
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel splicing variants from RON proto-oncogene pre-mRNA.
Moon H; Cho S; Yang X; Zhou J; Loh TJ; Zheng X; Shen H
Oncol Rep; 2012 Dec; 28(6):2217-20. PubMed ID: 22993024
[TBL] [Abstract][Full Text] [Related]
8. Novel splicing variants of recepteur d'origine nantais (RON) tyrosine kinase involving exons 15-19 in lung cancer.
Krishnaswamy S; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Lung Cancer; 2016 Feb; 92():41-6. PubMed ID: 26775595
[TBL] [Abstract][Full Text] [Related]
9. Decoding a cancer-relevant splicing decision in the RON proto-oncogene using high-throughput mutagenesis.
Braun S; Enculescu M; Setty ST; Cortés-López M; de Almeida BP; Sutandy FXR; Schulz L; Busch A; Seiler M; Ebersberger S; Barbosa-Morais NL; Legewie S; König J; Zarnack K
Nat Commun; 2018 Aug; 9(1):3315. PubMed ID: 30120239
[TBL] [Abstract][Full Text] [Related]
10. The gene encoding the splicing factor SF2/ASF is a proto-oncogene.
Karni R; de Stanchina E; Lowe SW; Sinha R; Mu D; Krainer AR
Nat Struct Mol Biol; 2007 Mar; 14(3):185-93. PubMed ID: 17310252
[TBL] [Abstract][Full Text] [Related]
11. Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway.
Liu X; Mayeda A; Tao M; Zheng ZM
J Virol; 2003 Feb; 77(3):2105-15. PubMed ID: 12525645
[TBL] [Abstract][Full Text] [Related]
12. The HNRNPA2B1-MST1R-Akt axis contributes to epithelial-to-mesenchymal transition in head and neck cancer.
Gupta A; Yadav S; Pt A; Mishra J; Samaiya A; Panday RK; Shukla S
Lab Invest; 2020 Dec; 100(12):1589-1601. PubMed ID: 32669614
[TBL] [Abstract][Full Text] [Related]
13. Repression of aberrant splicing in human beta-globin pre-mRNA with HbE mutation by antisense oligoribonucleotide or splicing factor SF2/ASF.
Shirohzu H; Yamaza H; Fukumaki Y
Int J Hematol; 2000 Jul; 72(1):28-33. PubMed ID: 10979205
[TBL] [Abstract][Full Text] [Related]
14. Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors.
Soret J; Bakkour N; Maire S; Durand S; Zekri L; Gabut M; Fic W; Divita G; Rivalle C; Dauzonne D; Nguyen CH; Jeanteur P; Tazi J
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8764-9. PubMed ID: 15939885
[TBL] [Abstract][Full Text] [Related]
15. A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene.
Moon H; Cho S; Loh TJ; Zhou J; Ghigna C; Biamonti G; Green MR; Zheng X; Shen H
Oncol Rep; 2014 Jan; 31(1):450-5. PubMed ID: 24189591
[TBL] [Abstract][Full Text] [Related]
16. Identification of the splice variants of Recepteur d'Origine nantais (RON) in lung cancer cell lines.
Krishnaswamy S; Bukhari I; Mohammed AK; Amer OE; Tripathi G; Alokail MS; Al-Daghri NM
Gene; 2018 Dec; 679():335-340. PubMed ID: 30223007
[TBL] [Abstract][Full Text] [Related]
17. ASF/SF2-like maize pre-mRNA splicing factors affect splice site utilization and their transcripts are alternatively spliced.
Gao H; Gordon-Kamm WJ; Lyznik LA
Gene; 2004 Sep; 339():25-37. PubMed ID: 15363843
[TBL] [Abstract][Full Text] [Related]
18. Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT).
Biamonti G; Bonomi S; Gallo S; Ghigna C
Cell Mol Life Sci; 2012 Aug; 69(15):2515-26. PubMed ID: 22349259
[TBL] [Abstract][Full Text] [Related]
19. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Pilch B; Allemand E; Facompré M; Bailly C; Riou JF; Soret J; Tazi J
Cancer Res; 2001 Sep; 61(18):6876-84. PubMed ID: 11559564
[TBL] [Abstract][Full Text] [Related]
20. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
